Neurizon Therapeutics Limited has released a press release.
Neurizon develops liquid formulation of NUZ-001
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- NUZ-001 Shows Significant Blood-Brain Barrier Penetration
- NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
- NUZ-001 Shows Promise in a Model of Huntington's Disease
- Last Patient Successfully Completes Treatment in OLE Study
- NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
Later from Neurizon Therapeutics
- Neurizon Enters Global Licensing Agreement with Elanco
- Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
- Positive feedback from FDA on strategy to lift clinical hold
- Neurizon Submits Clinical Hold Complete Response to FDA
- Neurizon Secures Loan Against 2025 R&D Tax Rebate
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics